


CLAIMS

1. A compound of formula (I):



or a pharmaceutically acceptable salt or a stereoisomer thereof;

wherein,

Z₁ is optionally substituted aryl, optionally substituted heterocyclyl or is absent;

Z₂ is optionally substituted aryl or optionally substituted heterocyclyl;

R₁ is optionally substituted cycloalkyl or optionally substituted saturated heterocyclyl;

R₂ at each occurrence is hydrogen, halogen, amino, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

R₃ at each occurrence is hydroxy, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl or -NR_aR_b;

R_a and R_b, independently for each occurrence, are hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

m, at each occurrence, is 0, 1 or 2; and


n, at each occurrence, is 0, 1, or 2.

2. The compound of claim 1, wherein Z₁ is an optionally substituted heterocyclyl.

3. The compound of claim 1 or 2, wherein Z₁ is a heterocyclyl selected from tetrazolyl, thienyl, triazolyl, pyrrolyl, pyridyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidyl, imidazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl, pyrazolyl, benzisoxazolyl, benzothiazolyl, benzofuranyl, benzothienyl, benzotriazinyl, phthalazinyl, thianthrene,


dibenzofuranyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinoliny, isoquinoliny, quinazoliny, quinoxaliny, pteridiny, 9H-carbazolyl, α -carboline, indoliziny, benzoisothiazolyl, benzoxazolyl, pyrrolopyridyl, furopyridiny, puriny, benzothiadiazolyl, benzooxadiazolyl, benzotriazolyl, benzotriadiazolyl, carbazolyl, dibenzothienyl, acridiny and pyrazolopyrimidyl.

4. The compound of any preceding claim, represented by formula (IA)



or a pharmaceutically acceptable salt thereof.

5. The compound of any one of claims 1 to 3, represented by formula (IB)



or a pharmaceutically acceptable salt thereof.

6. The compound of any preceding claim, wherein Z_2 is a heterocyclyl.

7. The compound of any preceding claim, wherein Z_2 is a heterocyclyl selected from azetidiny, oxetanyl, imidazolidiny, pyrrolidiny, oxazolidiny, thiazolidiny, pyrazolidiny, tetrahydrofuranyl, piperidiny, piperaziny, tetrahydropyranyl, morpholiny, thiomorpholiny, 1,4-dioxanyl, tetrazolyl, thienyl, triazolyl, pyrrolyl, pyridiny, tetrahydropyridiny, pyranly, pyraziny, pyridaziny, pyrimidyl, piperaziny, imidazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl, pyrazolyl, indoliny, indolylmethyl, 2-aza-bicyclo[2.2.2]octanyl, chromanyl, xanthenyl and pyrrolopyridyl.

8. The compound of any preceding claim, wherein Z_2 is pyrrolidinyl, piperidinyl, piperazinyl, pyridinyl, pyrimidyl, tetrahydropyridinyl or pyrrolopyridyl.
9. The compound of any preceding claim, wherein Z_2 is pyrrolidinyl or pyridinyl.
10. The compound of any preceding claim, wherein R_1 is optionally substituted saturated heterocyclyl.
11. The compound of any preceding claim, wherein R_1 is saturated heterocyclyl; optionally substituted with halogen, hydroxyl or hydroxyalkyl.
12. The compound of any preceding claim, wherein R_1 is optionally substituted azetidiny, piperidinyl, morpholinyl, pyrrolidinyl or azabicyclooctanyl.
13. The compound of any preceding claim, wherein R_1 is piperidinyl.
14. The compound of any preceding claim, wherein R_2 is optionally substituted alkyl.
15. The compound of any preceding claim, wherein R_2 is alkyl, optionally substituted with heterocyclyl.
16. The compound of any one of claims 1 to 13, wherein R_2 is hydrogen.
17. The compound of any one of claims 1 to 13, wherein R_2 is cyclopropyl.
18. The compound of any one of claims 1 to 17, wherein R_3 is halogen, alkyl, haloalkyl, - NR_aR_b , cycloalkyl, hydroxyl or hydroxyalkyl.
19. The compound of any preceding claim, wherein R_3 is methyl, hydroxyl, or amino.
20. The compound of any preceding claim, wherein R_3 is hydroxyl or amino.
21. The compound of claim 1, wherein

Z₁ is optionally substituted aryl or optionally substituted heterocyclyl;

Z₂ is aryl or heterocyclyl;

R₁ optionally substituted cycloalkyl, optionally substituted saturated heterocyclyl, or optionally substituted saturated bicyclic heterocyclyl;

R₂ is amino, alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, arylalkyl or heterocyclylalkyl;

R₃ is hydroxy, alkyl, alkoxy, or -NR_aR_b;

R_a and R_b, independently for each occurrence, are hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, arylalkyl or heterocyclylalkyl;

m is 1; and

n is 1.

22. The compound of claim 1, wherein

Z₁ is optionally substituted heterocyclyl;

Z₂ is optionally substituted saturated heterocyclyl;

R₁ is optionally substituted heterocyclyl;

R₂ is alkyl;

R₃ is hydroxy, alkyl, or amino;

m is 1; and

n is 1.

23. A compound selected from:

Compound No.	IUPAC Name
1.	N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
2.	N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
3.	(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)picolinamide;
4.	(S)-2-(3-aminopyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-

	yl)oxazole-4-carboxamide;
5.	(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)oxazole-4-carboxamide;
6.	(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)oxazole-4-carboxamide;
7.	(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)picolinamide
8.	(S)-6-(3-aminopyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)picolinamide;
9.	(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)picolinamide;
10.	(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)oxazole-4-carboxamide;
11.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
12.	N-(5-(3-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
13.	N-(5-(3-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
14.	N-(5-(3-fluoropiperidin-1-yl)-2-methyl-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
15.	(S)-2-(2-acetamidopyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;
16.	N-(5-(3-fluoropiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
17.	N-(5-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
18.	(S)-2-(2-aminopyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;
19.	N-(5-(4-fluoropiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-

	4-yl)oxazole-4-carboxamide;
20.	N-(5-(4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
21.	(S)-2-(2,6-dimethylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;
22.	(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
23.	(S)-2-(2-aminopyridin-3-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide Hydrochloride;
24.	6-((S)-3-hydroxypyrrolidin-1-yl)-N-(5-((R)-3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)picolinamide;
25.	6-((S)-3-hydroxypyrrolidin-1-yl)-N-(5-((S)-3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl) picolinamide;
26.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxazole-4-carboxamide;
27.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
28.	(S)-2-(2-amino-3-fluoropyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;
29.	(R)-2-(2-aminopyridin-3-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;
30.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(4-methylpiperazin-1-yl)oxazole-4-carboxamide;
31.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(piperazin-1-yl)oxazole-4-carboxamide hydrochloride;
32.	(S)-N-(1-ethyl-5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
33.	(S)-N-(1-cyclopropyl-5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
34.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(1,2,3,6-

	tetrahydropyridin-4-yl)oxazole-4-carboxamide hydrochloride;
35.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyrimidin-4-yl)oxazole-4-carboxamide hydrochloride;
36.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-4-methyl-2-(2-methylpyridin-4-yl) oxazole-5-carboxamide hydrochloride;
37.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide hydrochloride;
38.	N-(5-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
39.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl) oxazole-5-carboxamide;
40.	N-(5-(4-hydroxy-4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
41.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-5-methyl-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
42.	(S)-2-(2-ethylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;
43.	2-(2-aminopyridin-4-yl)-N-(5-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;
44.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-(piperidin-4-ylmethyl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
45.	N-(5-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
46.	(S)-2-(2-cyclopropylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;
47.	N-(5-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride; and
48.	(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

24. A pharmaceutical composition comprising at least one compound according to any preceding claim, or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.
25. Use of a compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt or a stereoisomer thereof, in the manufacture of a medicament for the treatment of an IRAK4-mediated disorder, disease, or condition.
26. The use of claim 25, wherein the IRAK4 mediated disorder, disease, or condition is selected from a cancer, a proliferative disorder, an inflammatory disorder, an autoimmune disease, a metabolic disorder, a hereditary disorder, a hormone-related disease, an immunodeficiency disorder, a condition associated with cell death, a destructive bone disorder, thrombin-induced platelet aggregation, liver disease and a cardiovascular disorder.
27. The use of claim 26, wherein the cancer or the proliferative disorder is selected from a solid tumor, benign or malignant tumor, carcinoma of the brain, kidney, liver, stomach, vagina, ovaries, gastric tumors, breast, bladder, colon, prostate, pancreas, lung, cervix, testis, skin, bone or thyroid; sarcoma, glioblastoma, neuroblastoma, gastrointestinal cancer, a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small-cell lung carcinoma, lymphomas, Hodgkins and Non-Hodgkins, a mammary carcinoma, follicular carcinoma, papillary carcinoma, seminoma, melanoma; and hematological malignancies selected from leukemia, diffuse large B-cell lymphoma (DLBCL), activated B-cell-like DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, acute lymphocytic leukemia, B-cell pro lymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, intravascular large B-cell lymphoma, plasmacytoma and multiple myeloma.
28. The use of claim 26, wherein the inflammatory disorder is selected from an ocular allergy, conjunctivitis, keratoconjunctivitis sicca, vernal conjunctivitis, allergic rhinitis, an autoimmune hematological disorder, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis,

myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease, irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine ophthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, primary biliary cirrhosis, uveitis, Sjogren's syndrome, interstitial lung fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis, chronic granulomatous disease, endometriosis, leptospirosis renal disease, glaucoma, retinal disease, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behcet's disease, incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndrome, asthma, acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivities, anaphylaxis, fibrositis, gastritis, gastroenteritis, nasal sinusitis, silica induced diseases, chronic obstructive pulmonary disease (COPD), cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation in conjunction with systemic sclerosis, inclusion body myositis, thyroiditis, Addison's disease, lichen planus, appendicitis, atopic dermatitis, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, cystitis, dacryoadenitis, dermatitis, juvenile rheumatoid arthritis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, Henoch-Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, vulvitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acute and chronic gout, chronic gouty arthritis, psoriasis, Cryopyrin Associated Periodic Syndrome (CAPS) and osteoarthritis.

29. Use of a compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt or a stereoisomer thereof, in the manufacture of a medicament for the treatment of a disease or condition associated with an MYD88 mutation.
30. The use of claim 29, wherein the disease or condition associated with an MYD88 mutation is selected from a cancer, a proliferative disorder, an inflammatory disorder, an autoimmune disease, a metabolic disorder, a hereditary disorder, a hormone-related disease, an immunodeficiency disorder, a condition associated with cell death, a destructive bone disorder, thrombin-induced platelet aggregation, liver disease and a cardiovascular disorder.
31. The use of claim 29, wherein the disease or condition is ulcerative colitis.
32. The use of claim 29, wherein the disease or condition is a lymphoma.
33. The use of claim 29, wherein the disease or condition is a cancer selected from diffuse large B-cell lymphoma and Waldenstrom's macroglobulinemia.